227 related articles for article (PubMed ID: 32733053)
1. Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.
Chelladurai P; Dabral S; Basineni SR; Chen CN; Schmoranzer M; Bender N; Feld C; Nötzold RR; Dobreva G; Wilhelm J; Jungblut B; Zhao L; Bauer UM; Seeger W; Pullamsetti SS
Sci Rep; 2020 Jul; 10(1):12864. PubMed ID: 32733053
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension.
Nozik-Grayck E; Woods C; Stearman RS; Venkataraman S; Ferguson BS; Swain K; Bowler RP; Geraci MW; Ihida-Stansbury K; Stenmark KR; McKinsey TA; Domann FE
Am J Physiol Lung Cell Mol Physiol; 2016 Jul; 311(1):L124-34. PubMed ID: 27233998
[TBL] [Abstract][Full Text] [Related]
3. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
4. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation.
Hess L; Moos V; Lauber AA; Reiter W; Schuster M; Hartl N; Lackner D; Boenke T; Koren A; Guzzardo PM; Gundacker B; Riegler A; Vician P; Miccolo C; Leiter S; Chandrasekharan MB; Vcelkova T; Tanzer A; Jun JQ; Bradner J; Brosch G; Hartl M; Bock C; Bürckstümmer T; Kubicek S; Chiocca S; Bhaskara S; Seiser C
PLoS Genet; 2022 Aug; 18(8):e1010376. PubMed ID: 35994477
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
6. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
7. Expression of Class I Histone Deacetylases in Ipsilateral and Contralateral Hemispheres after the Focal Photothrombotic Infarction in the Mouse Brain.
Demyanenko S; Neginskaya M; Berezhnaya E
Transl Stroke Res; 2018 Oct; 9(5):471-483. PubMed ID: 29218547
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis.
Korfei M; Skwarna S; Henneke I; MacKenzie B; Klymenko O; Saito S; Ruppert C; von der Beck D; Mahavadi P; Klepetko W; Bellusci S; Crestani B; Pullamsetti SS; Fink L; Seeger W; Krämer OH; Guenther A
Thorax; 2015 Nov; 70(11):1022-32. PubMed ID: 26359372
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Khabele D; Son DS; Parl AK; Goldberg GL; Augenlicht LH; Mariadason JM; Rice VM
Cancer Biol Ther; 2007 May; 6(5):795-801. PubMed ID: 17387270
[TBL] [Abstract][Full Text] [Related]
10. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
11. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.
Chen F; Li X; Aquadro E; Haigh S; Zhou J; Stepp DW; Weintraub NL; Barman SA; Fulton DJR
Free Radic Biol Med; 2016 Oct; 99():167-178. PubMed ID: 27498117
[TBL] [Abstract][Full Text] [Related]
13. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity.
Fu Y; Zhang P; Ge J; Cheng J; Dong W; Yuan H; Du Y; Yang M; Sun R; Jiang H
Int J Biochem Cell Biol; 2014 Sep; 54():68-77. PubMed ID: 25019367
[TBL] [Abstract][Full Text] [Related]
15. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS
Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029
[TBL] [Abstract][Full Text] [Related]
18. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
19. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
